what is the best glp 1 on the market Glucagon-like Peptide-1 (GLP-1) Agonists Size and Companies Force Factor Super GLP GLP-1 Receptor Agonist Market Growth

Timing considerations also matter

An Z, Prigeon RL, DAlessio DA: Improved glycemic control enhances the incretin effect in patients with type 2 diabetes

STEP 1 Trial Results (Published in New England Journal of Medicine, 2021): 1,961 adults with obesity or overweight with weight-related health conditions 68-week treatment period Semaglutide 2.4mg weekly injection + lifestyle intervention Average weight loss: 14.9% of total body weight (compared to 2.4% with placebo) 50.5% of participants lost 15% of body weight 32.0% of participants lost 20% of body weight STEP 2 Trial (Adults with Type 2 Diabetes): Demonstrated 9.6% average weight loss in patients with diabetes Also showed improvements in glycemic control (HbA1c reduction) STEP 3 Trial (Intensive Behavioral Therapy Component): Combined semaglutide with intensive behavioral therapy Average weight loss: 16.0% of total body weight Important context about clinical data: These trials studied FDA-approved brand-name semaglutide at specific doses with structured lifestyle interventions including dietary counseling, exercise recommendations, and behavioral support

Thiazolidinediones (TZD) were expected to improve the asthma outcomes as they reduce insulin resistance by activating PPAR- pathways

Hypoglycemia is rare with monotherapy but can occur if combined with insulin or sulfonylureas